权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Identification of Long Non-coding RNAs as Novel Biomarkers for Heterogeneous Glioblastomas

鉴定长非编码 RNA 作为异质性胶质母细胞瘤的新型生物标志物

基本信息

批准号：
9321295
负责人：
Shi-Yuan Cheng
金额：
$ 16.57万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-01 至 2019-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9321295
关键词：
19q Achievement Affect Algorithms Area Biological Markers Biology Brain Brain Neoplasms Cancer Patient Catalogs Cell Proliferation Cell physiology Central Nervous System Neoplasms Cessation of life Characteristics Clinical Code Colorectal Neoplasms Combined Modality Therapy Communities Complex Data Detection Development Diagnosis Ensure Epidermal Growth Factor Receptor Exons Female Future Gene Expression Gene Expression Profile Gene Expression Regulation Genes Genetic Transcription Glioblastoma Glioma Goals Heterogeneity Human Internet Length Machine Learning Malignant - descriptor Malignant Neoplasms Malignant neoplasm of brain Measures Messenger RNA Morphologic artifacts Mutation Neoplasm Metastasis Newly Diagnosed Nucleotides Operative Surgical Procedures Outcome Pathogenesis Pathway Analysis Patient-Focused Outcomes Patients Pattern Primary Neoplasm RNA RNA Splicing Regulation Regulator Genes Research Resources Role Sampling Scanning Solid Neoplasm Specificity Specimen Stratification Techniques The Cancer Genome Atlas Time Tissue Banks Tissues Transcript United States Universities Untranslated RNA Validation Work X Inactivation base cancer biomarkers cancer type clinical Diagnosis clinical care cohort differential expression flexibility gene function histone modification indexing innovation molecular marker molecular subtypes multidisciplinary novel novel marker novel therapeutics oligo (dT)outcome forecast peripheral blood personalized medicine precision medicine prognostic prognostic tool public health relevance success targeted treatment transcriptome transcriptome sequencing transcriptomics tumor tumorigenesis

项目摘要

PROJECT SUMMARY Glioblastoma multiforme (GBM) is the most malignant form of brain tumors with more than 18,000 newly diagnosed patients and 13,000 deaths annually in the United States. The prognosis for GBM remains dismal with a median survival time of GBM patients of 14 to 16 months after diagnosis. A hallmark of malignant GBM is their high heterogeneity within the tumors. This unique characteristic manifests to molecular subtypes of GBM that display unique patterns of pathogenesis, biology, and prognosis. While specific molecular markers are of value in clinical care (e.g., IDH1/2 mutations, 1p/19q co-deletion), significant improvement in prognostic stratification and targeted therapeutics are urgently needed. With the ultimate goal of realizing the full potential of personalized and precision medicine, we propose to interrogate long non-coding RNAs (lncRNAs) in a cohort of clinical GBM specimens. LncRNAs are a class of non-coding RNAs that have emerged as critical modulators in various cellular processes through gene regulation. Previous studies including The Cancer Genome Atlas (TCGA), though limited by their profiling technique not designed for non-coding RNAs, have suggested that lncRNAs are abundant in human cancers and are highly cancer-type-specific. In particular, lncRNAs have been implicated in brain function and glioma development. Specifically, in this exploratory project, we will apply the Ribo-Zero-based transcriptomic sequencing (RNA-seq) to comprehensively characterize lncRNAs in 100 clinical GBM samples that have been collected at the Northwestern University Brain Tumor Tissue Bank (Aim 1a). In contrast to the oligo(dT)-based RNA-seq that was used by previous studies, including TCGA, the Ribo-Zero-based technique is optimized for non-coding RNA transcripts, thus offering a great advantage for profiling all potentially functional lncRNAs in GBM. Notably, a novel detection algorithm based on machine learning will be developed to provide a more flexible and universal framework of lncRNA detection using RNA-seq. Though restricted to those lncRNAs shared between our GBM data and the oligo(dT)-based TCGA, we will evaluate the tissue-specificity of lncRNAs detected in GBM using TCGA data on several solid tumors (Aim 1b). After characterizing the landscape of lncRNAs in GBM, we will evaluate whether lncRNAs are associated with the clinical outcomes of GBM patients, and evaluate the feasibility of integrating lncRNAs and gene-level transcripts into a prognostic tool (Aim 2a). This proposal will enable us to employ these novel biomarkers for the prognosis of GBM as well as future functional studies. In addition, we will utilize co-expression network analysis to assign functions to the detected lncRNAs in GBM. An integrated, internet-based catalog will be constructed to provide a resource of lncRNAs in GBM that will benefit the general research community in this new area (Aim 2b). Finally, the PIs have assembled an outstanding research team with significant achievements in relevant research areas and complimentary expertise, therefore ensuring the success of this multidisciplinary and highly innovative project.

项目总结